

Daniel A Alcolea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4224543/publications.pdf>

Version: 2024-02-01

169
papers

9,114
citations

61984

43
h-index

49909

87
g-index

193
all docs

193
docs citations

193
times ranked

10955
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	7.6	17
2	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
4	The A β 1-42/A β 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A β 1-42 alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	6.2	18
5	Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. <i>Cell Metabolism</i> , 2022, 34, 269-284.e9.	16.2	13
6	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	6.2	10
7	Neuropsychological deficits in patients with cognitive complaints after COVID-19. <i>Brain and Behavior</i> , 2022, 12, e2508.	2.2	64
8	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	2.8	7
9	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	3.4	20
10	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	10.8	7
11	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
12	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
13	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.8	22
14	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1058-1063.	2.3	4
15	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	5.9	47
16	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
17	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	4.1	13
18	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 70-77.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.8	27
20	Heterozygous <i>APOE</i> Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 579-582.	3.2	10
21	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	21.4	198
22	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.8	34
23	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	5.9	12
24	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.8	11
25	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	2.6	18
26	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.8	23
27	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
28	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	1.9	30
29	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	6.2	6
30	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	12.8	33
31	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	9.0	32
32	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	5.3	7
33	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	10.2	29
34	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 37.	8.0	8
35	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 160.	6.2	5
36	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	3.2	7

#	ARTICLE	IF	CITATIONS
37	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	1
38	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	2.4	6
39	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4
40	Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The Fundaci3 ACE Biomarker Research Program (FACEBREP). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
41	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	8.0	32
42	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
43	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	7
44	Calsyntenin4 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
45	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
46	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
47	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
48	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	6.1	24
49	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. <i>Cerebral Cortex</i> , 2020, 30, 2083-2098.	2.9	25
50	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	6.2	33
51	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	54
52	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	2.4	7
53	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.1	19
54	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	2.6	7

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	10.8	21
56	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.8	1
57	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e041255.	0.8	0
58	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020, 16, e041500.	0.8	0
59	The effect of APOE ε4 in Alzheimer's disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e042889.	0.8	0
60	1 H-MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.8	0
61	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044772.	0.8	0
62	Which pre-analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. <i>Alzheimer's and Dementia</i> , 2020, 16, e045060.	0.8	0
63	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045268.	0.8	0
64	Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047017.	0.8	0
65	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.8	1
66	Annexin A5 prevents amyloid-β2-induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	3.3	18
67	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	2.4	25
68	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	13.7	164
69	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001516.	2.8	7
70	The cognitive aftermath of COVID-19. <i>Brain Communications</i> , 2020, 2, .	3.3	8
71	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	2.6	25
72	Assessing circular RNAs in Alzheimer's disease and frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2020, 92, 7-11.	3.1	30

#	ARTICLE	IF	CITATIONS
73	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 1252.	4.1	8
74	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
75	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	14.8	48
76	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	3.7	44
77	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	3.7	104
78	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.8	46
79	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	7.7	87
80	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	3.3	33
81	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	7.6	45
82	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
83	ICP148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P119.	0.8	0
84	O2A01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P558.	0.8	0
85	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	3.7	70
86	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	3.7	13
87	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019, 490, 98-101.	1.1	17
88	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	3.8	115
89	Elevated YKL-40 and low sAPP β :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	1.9	17
90	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	2.4	37

#	ARTICLE	IF	CITATIONS
91	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	3.1	8
92	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
93	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.8	122
94	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
95	Association of Cerebral Amyloid- β 2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
96	P4-076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2018, 14, P1463.	0.8	0
97	P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P777.	0.8	0
98	P3-394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1248.	0.8	0
99	P1-277: CORRELATION BETWEEN INNOTEST [®] AND THE FULLY AUTOMATED LUMIPULSE [®] G PLATFORM FOR THE ANALYSIS OF β 2 AMYLOID 142 AND TOTAL TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P388.	0.8	1
100	CSF sAPP β 2, YKL-40, and NfL along the ALS-FTD spectrum. <i>Neurology</i> , 2018, 91, e1619-e1628.	1.1	59
101	P1-293: IDENTIFICATION OF EXOSOMAL MICRORNAs AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P398.	0.8	0
102	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
103	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	10.2	140
104	Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 609.	2.8	59
105	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	2.6	16
106	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018, 9, 34691-34698.	1.8	57
107	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	2.6	5
108	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.8	47

#	ARTICLE	IF	CITATIONS
109	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	2.6	28
110	CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.1	100
111	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
112	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017, 53, 192.e1-192.e4.	3.1	24
113	[P1-366]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P399.	0.8	0
114	[P3-274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1048.	0.8	0
115	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017, 13, 1072-1074.	0.8	5
116	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	4.0	45
117	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 499-509.	0.8	65
118	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	4.0	119
119	[P1-238]: THE SAPP β /YKL-40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P335.	0.8	0
120	[P4-505]: CORTICAL MICROSTRUCTURAL CHANGES IN FRONTOTEMPORAL LOBAR DEGENERATION: A NEW IMAGING BIOMARKER. <i>Alzheimer's and Dementia</i> , 2017, 13, P1533.	0.8	0
121	[P2-259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR AD-RELATED SYNAPSE LOSS. <i>Alzheimer's and Dementia</i> , 2017, 13, P712.	0.8	0
122	[O3-10-03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.8	3
123	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	1.8	51
124	Cerebrospinal Fluid Anti-Amyloid- β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1-7.	2.6	43
125	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 539-546.	2.6	38
126	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	6.9	392

#	ARTICLE	IF	CITATIONS
127	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1327-1333.	2.6	7
128	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2016, 55, 1489-1496.	2.6	14
129	P4122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0
130	O50204: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2016, 12, P380.	0.8	4
131	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
132	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
133	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 242 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	1.1	140
134	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.7	13
135	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179
136	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. Alzheimer Disease and Associated Disorders, 2015, 29, 353-356.	1.3	8
137	Effect of REST on brain metabolism in the Alzheimer disease continuum. Annals of Neurology, 2015, 78, 661-662.	5.3	2
138	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget, 2015, 6, 26663-26674.	1.8	92
139	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	4.3	39
140	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
141	Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
142	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.1	131
143	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	3.1	75
144	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166

#	ARTICLE	IF	CITATIONS
145	P3-230: CSF β -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
146	IC-P-217: CSF β -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
147	Reply. Annals of Neurology, 2014, 75, 460-461.	5.3	0
148	Relationship Between β -Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 157-167.	2.6	106
149	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	12.4	600
150	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Human Molecular Genetics, 2014, 23, 749-754.	2.9	98
151	Cerebrospinal fluid β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Annals of Neurology, 2014, 76, 223-230.	5.3	110
152	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	1.9	55
153	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- β Peptide Aggregation. Journal of Alzheimer's Disease, 2014, 40, 643-657.	2.6	41
154	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	2.6	53
155	P2-121: CHARACTERIZATION OF THE CEREBROSPINAL FLUID PROTEOME IN THE SEARCH FOR BIOMARKERS OF PRECLINICAL AD. , 2014, 10, P515-P515.		0
156	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
157	P2-088: RELATIONSHIP BETWEEN CSF YKL-40 AND CORTICAL THICKNESS. , 2014, 10, P503-P503.		0
158	P2-132: BIOMARKERS IN CEREBRAL AMYLOID ANGIOPATHY-RELATED INFLAMMATION. , 2014, 10, P519-P519.		0
159	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 2013, 74, 655-668.	5.3	171
160	Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. Journal of Neural Transmission, 2013, 120, 807-812.	2.8	63
161	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica, 2013, 125, 201-213.	7.7	103
162	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344

#	ARTICLE	IF	CITATIONS
163	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 469-476.	1.9	10
164	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. Journal of Alzheimer's Disease, 2013, 36, 67-77.	2.6	53
165	Rapidly Progressive Dementia. Alzheimer Disease and Associated Disorders, 2012, 26, 267-271.	1.3	40
166	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. Neurobiology of Aging, 2012, 33, 1851.e17-1851.e19.	3.1	13
167	The Effect of MAPT H1 and APOE ϵ 4 on Transition from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2011, 22, 1065-1071.	2.6	24
168	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.5	125
169	Remote cerebral hematomas in patients treated with intravenous rt-PA. Journal of Neurology, 2010, 257, 1062-1066.	3.6	16